干扰素α-2b加利巴维林与干扰素α-2b加利巴维林相比,用于慢性型肝炎的初始治疗:一项随机试验
M P Manns1, J G McHutchison, S C Gordon
1Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany. manns.michael@mh-hannover.de
Lancet (London, England)
|October 5, 2001
概括
干扰素α-2b加上利巴维林显著改善了慢性型肝炎患者的持续病毒学反应 (SVR) 率. 高剂量的干扰素显示出最大的疗效,特别是对于那些患有型肝炎病毒基因型1的人.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 历史上,慢性型肝炎的治疗在使用干扰素α-2b加上瑞巴维林时,实现了41%的持续病毒学反应 (SVR) 率.
- 进行了一项随机试验,比较干扰素α-2b加瑞巴维林与干扰素α-2b加瑞巴维林用于慢性型肝炎.
研究的目的:
- 为了比较干扰素α-2b加里巴维林与干扰素α-2b加里巴维林在治疗慢性肝炎C的疗效.
- 为了确定结合疗法中干扰素α-2b的最佳剂量方案.
主要方法:
- 1530名患有慢性型肝炎的患者被随机分配到三组,接受不同的干扰素和利巴维林治疗方案.
- 主要终点是SVR率,定义为24周治疗后无法检测到的C型肝炎病毒 (HCV) RNA.
- 分析包括接受至少一剂研究药物的患者.
主要成果:
- 高剂量干扰素组与低剂量干扰素 (47%) 和标准干扰素 (47%) 相比,实现了显著更高的SVR率 (54%).
- 在患有HCV基因型1的患者中,SVR率为42% (高剂量干扰素),34% (低剂量干扰素) 和33% (标准干扰素).
- 患有HCV基因型2和3的患者在所有组中约有80%的SVR率;体重是SVR的预测因素.
结论:
- 干扰素α-2b (每周1.5微克/千克) 加上利巴维林的组合是慢性型肝炎最有效的治疗方法.
- 这种治疗益处在感染C型肝炎病毒基因型1的患者中最为明显.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...


